Aubagio® delays onset of clinically definite MS, study
Aubagio® delays onset of clinically definite MS, study
Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1458 Views
-
Last post by NHE
-
- 0 Replies
- 794 Views
-
Last post by NHE
-
- 0 Replies
- 2170 Views
-
Last post by frodo
-
- 0 Replies
- 1072 Views
-
Last post by NHE
-
- 1 Replies
- 993 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1301 Views
-
Last post by frodo
-
- 0 Replies
- 1559 Views
-
Last post by NHE
-
- 0 Replies
- 1996 Views
-
Last post by vesta
-
- 0 Replies
- 1584 Views
-
Last post by frodo